What is Atea Pharmaceuticals, Inc.'s earnings per share (EPS)?

Atea Pharmaceuticals, Inc. (AVIR) reported diluted earnings per share of -$1.94 for fiscal year 2025. This represents a 3.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atea Pharmaceuticals, Inc. (AVIR) Financials

AVIR

FY2025 annual

Revenue Not reported for FY2025

Net Income -$158.0M +6.0% YoY

EPS (Diluted) -$1.94 +3.0% YoY

Operating Cash Flow -$132.0M +2.6% YoY

Market Cap $406.6M as of Oct 6, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 2.0x on $204.2M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AVIR SEC filings page.

This page shows Atea Pharmaceuticals, Inc. (AVIR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AVIR FY2025 2026-10-04

Atea operates as a cash-consuming development business: research investment continues while assets and equity shrink.

In FY2025, operating cash flow of -$132M remained close to the net loss of $158M, so accounting losses broadly translated into cash consumption. With R&D at $148M and SG&A at $32.9M, the expense structure is centered on development rather than broad cost reduction.

Total assets fell from $464.7M in FY2024 to $315.2M in FY2025, indicating that losses are being funded by steadily consuming the balance sheet. The current ratio also fell from 24.9x to 7.8x, leaving less excess liquidity relative to near-term obligations even though current assets still exceed current liabilities.

Reported cash, cash equivalents, and investments equaled 27.4 months of the latest annual operating outflow, a balance-sheet comparison rather than an operating achievement. In FY2025, investing cash flow of $188.8M outweighed operating cash flow of -$132.0M, meaning reported resources were supplemented by non-operating cash inflows rather than by the business’s activities.

Financial Health Signals

Financial health score not available

Atea Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Atea Pharmaceuticals, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Atea Pharmaceuticals, Inc. reported a net loss of $158.0M while operations used $132.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$35.0M

YoY+15.1%

QoQ+26.9%

Atea Pharmaceuticals, Inc.'s EBITDA was -$35.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.1% from the same quarter a year earlier. Against the prior quarter it is up 26.9%.

Net Income

-$32.9M

YoY+11.4%

QoQ+27.5%

Atea Pharmaceuticals, Inc. reported -$32.9M in net income in Q2 2026. This represents an increase of 11.4% from the same quarter a year earlier. Against the prior quarter it is up 27.5%.

EPS (Diluted)

-$0.41

YoY+6.8%

QoQ+28.1%

Atea Pharmaceuticals, Inc. earned -$0.41 per diluted share (EPS) in Q2 2026. This represents an increase of 6.8% from the same quarter a year earlier. Against the prior quarter it is up 28.1%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$76.5M

YoY-12.7%

QoQ-3.5%

5Y CAGR-37.7%

Atea Pharmaceuticals, Inc. held $76.5M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

80M

YoY+1.1%

QoQ+0.2%

5Y CAGR-0.6%

Atea Pharmaceuticals, Inc. had 80M shares outstanding in Q2 2026. This represents an increase of 1.1% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-16.1%

YoY-5.9pp

QoQ+3.3pp

Atea Pharmaceuticals, Inc.'s ROE was -16.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$28.1M

YoY-12.8%

QoQ-31.6%

Atea Pharmaceuticals, Inc. invested $28.1M in research and development in Q2 2026. This represents a decrease of 12.8% from the same quarter a year earlier. Against the prior quarter it is down 31.6%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

AVIR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVIR quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY22DEF 14A	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Revenue	N/A	N/A	N/A	N/A	N/A	$351.4M+622.5%	$48.6M	N/A	N/A
R&D Expenses	N/A	$148.0M+2.7%	$144.1M+26.1%	$114.2M+39.4%	$81.9M-51.0%	$167.2M+339.7%	$38.0M+273.9%	$10.2M+52.4%	$6.7M
SG&A Expenses	N/A	$32.9M-32.7%	$48.8M-2.1%	$49.9M+2.5%	$48.7M+6.4%	$45.8M+111.6%	$21.6M+387.6%	$4.4M+58.4%	$2.8M
Operating Income	N/A	-$180.9M+6.3%	-$192.9M-17.5%	-$164.2M-25.7%	-$130.7M-194.4%	$138.4M+1354.6%	-$11.0M+24.5%	-$14.6M-54.1%	-$9.5M
EBITDA	N/A	-$180.5M+6.3%	-$192.5M-17.6%	-$163.7M-25.6%	-$130.4M-194.2%	$138.4M+1357.0%	-$11.0M+24.5%	-$14.6M-54.2%	-$9.5M
Income Tax	N/A	-$6.2M-766.2%	$925K-9.1%	$1.0M+128.4%	-$3.6M-120.6%	$17.4M	N/A	N/A	N/A
Net Income	N/A	-$158.0M+6.0%	-$168.0M-23.5%	-$136.0M-17.2%	-$116.0M-195.9%	$121.0M+1205.3%	-$10.9M+22.0%	-$14.0M-54.8%	-$9.1M
EPS (Basic)	N/A	-$1.94+3.0%	-$2.00-22.7%	-$1.63-17.3%	-$1.39-195.2%	$1.46+386.3%	-$0.51+63.3%	-$1.39	N/A
EPS (Diluted)	-$2.08	-$1.94+3.0%	-$2.00-22.7%	-$1.63-17.3%	-$1.39-201.5%	$1.37	-$0.51	-$1.39	N/A
Diluted Shares (Avg)	N/A	81M-3.3%	84M+1.0%	83M+0.2%	83M-5.7%	88M	22M	10M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$28.1M-12.8%	$41.1M+39.0%	N/A	$38.3M+46.6%	$32.3M-7.0%	$29.6M-48.6%	N/A	$26.2M-7.2%
SG&A Expenses	$6.9M-23.4%	$6.9M-27.3%	N/A	$7.2M-34.6%	$9.1M-25.8%	$9.5M-22.7%	N/A	$11.0M-12.4%
Operating Income	-$35.1M+15.1%	-$48.0M-23.0%	N/A	-$45.6M-22.5%	-$41.3M+11.9%	-$39.0M+44.1%	N/A	-$37.2M+8.8%
EBITDA	-$35.0M+15.1%	-$47.9M-23.0%	N/A	-$45.5M-22.5%	-$41.2M+11.9%	-$38.9M+44.1%	N/A	-$37.1M+8.8%
Income Tax	$24K-88.4%	$50K-75.4%	N/A	$196K-13.3%	$207K-14.8%	$203K-12.1%	N/A	$226K+2.3%
Net Income	-$32.9M+11.4%	-$45.4M-32.6%	N/A	-$42.0M-35.0%	-$37.2M+8.3%	-$34.3M+45.7%	N/A	-$31.2M+6.0%
EPS (Basic)	-$0.41+6.8%	-$0.57-42.5%	-$0.57-42.5%	-$0.53-43.2%	-$0.44+8.3%	-$0.40+46.7%	-$0.40+14.9%	-$0.37+7.5%
EPS (Diluted)	-$0.41+6.8%	-$0.57-42.5%	-$0.57-42.5%	-$0.53-43.2%	-$0.44+8.3%	-$0.40+46.7%	-$0.40+14.9%	-$0.37+7.5%
Diluted Shares (Avg)	80M-4.4%	79M-7.0%	N/A	79M-6.4%	84M-0.6%	85M+1.5%	N/A	84M+1.2%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

AVIR Balance Sheet

AVIR quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY22DEF 14A	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$315.2M-32.2%	$464.7M-21.9%	$595.0M-10.8%	$666.7M-13.7%	$772.9M-10.5%	$863.6M+3812.6%	$22.1M	N/A
Current Assets	$311.0M-32.7%	$462.4M-21.7%	$590.5M-10.7%	$660.9M-14.4%	$772.4M-10.5%	$863.5M+3841.0%	$21.9M	N/A
Cash & Equivalents	$95.7M+47.9%	$64.7M-55.0%	$143.8M-23.7%	$188.5M-75.3%	$764.4M-10.1%	$850.1M+3824.6%	$21.7M-37.2%	$34.5M
Short-Term Investments	$206.1M-47.2%	$390.0M-10.2%	$434.3M-5.2%	$458.2M	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$39.8M+54.2%	$25.8M-35.1%	$39.8M+52.2%	$26.1M-58.4%	$62.8M-80.1%	$315.8M+340.8%	$71.6M	N/A
Current Liabilities	$39.8M+113.9%	$18.6M-42.5%	$32.4M+75.2%	$18.5M-67.5%	$56.9M-82.0%	$315.8M+12869.0%	$2.4M	N/A
Non-Current Liabilities	$0-100.0%	$7.2M-2.7%	$7.4M-3.4%	$7.7M+29.1%	$5.9M+16377.8%	$36K-99.9%	$69.2M	N/A
Total Equity	$275.4M-37.2%	$438.9M-21.0%	$555.2M-13.3%	$640.6M-9.8%	$710.1M+29.6%	$547.8M+1205.1%	-$49.6M-37.1%	-$36.2M
Retained Earnings	-$522.6M-43.5%	-$364.2M-86.0%	-$195.8M-227.1%	-$59.9M-206.9%	$56.0M+186.0%	-$65.2M-20.2%	-$54.2M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$232.3M-40.7%	$267.1M-39.3%	$315.2M-32.2%	$343.0M-30.1%	$391.6M-23.3%	$440.0M-20.4%	$464.7M-21.9%	$491.0M-19.3%
Current Assets	$228.7M-40.7%	$263.2M-39.3%	$311.0M-32.7%	$336.1M-31.0%	$385.6M-23.8%	$433.7M-21.0%	$462.4M-21.7%	$486.9M-19.3%
Cash & Equivalents	$76.5M-12.7%	$79.3M-33.6%	$95.7M+47.9%	$77.3M-21.4%	$87.7M-64.0%	$119.4M-25.8%	$64.7M-55.0%	$98.5M-28.6%
Short-Term Investments	$142.9M-51.1%	$176.7M-42.3%	$206.1M-47.2%	$252.0M-34.4%	$292.0M+12.8%	$306.0M-19.6%	$390.0M-10.2%	$384.4M-15.9%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$28.1M+3.4%	$33.4M+15.5%	$39.8M+54.2%	$27.2M-16.2%	$27.2M-19.8%	$28.9M-40.6%	$25.8M-35.1%	$32.4M+23.1%
Current Liabilities	$28.1M+39.8%	$33.4M+53.4%	$39.8M+113.9%	$20.2M-19.9%	$20.1M-24.4%	$21.7M-47.4%	$18.6M-42.5%	$25.2M+33.3%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$0-100.0%	$7.0M-3.3%	$7.1M-3.1%	$7.1M-2.9%	$7.2M-2.7%	$7.2M-2.8%
Total Equity	$204.2M-44.0%	$233.7M-43.1%	$275.4M-37.2%	$315.8M-31.1%	$364.4M-23.5%	$411.1M-18.5%	$438.9M-21.0%	$458.5M-21.2%
Retained Earnings	-$600.9M-37.9%	-$568.0M-42.5%	-$522.6M-43.5%	-$477.7M-44.5%	-$435.7M-45.4%	-$398.5M-53.9%	-$364.2M-86.0%	-$330.7M-111.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

AVIR Cash Flow Statement

AVIR quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY22DEF 14A	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$152.1M	-$132.0M+2.6%	-$135.5M-58.7%	-$85.4M+29.4%	-$121.0M-39.1%	-$87.0M-129.3%	$296.7M+2413.0%	-$12.8M-62.2%	-$7.9M
Depreciation & Amortization	N/A	$416K0.0%	$416K0.0%	$416K+60.0%	$260K+796.6%	$29K+52.6%	$19K+11.8%	$17K0.0%	$17K
Stock-Based Compensation	N/A	$20.7M-60.0%	$51.8M+4.7%	$49.4M+5.8%	$46.7M+17.9%	$39.6M+431.3%	$7.5M+1095.0%	$624K+50.7%	$414K
Capital Expenditures	N/A	N/A	N/A	N/A	$1.9M+48475.0%	$4K-84.6%	$26K+1200.0%	$2K-83.3%	$12K
Free Cash Flow	N/A	N/A	N/A	N/A	-$122.9M-41.3%	-$87.0M-129.3%	$296.7M+2412.4%	-$12.8M-62.0%	-$7.9M
Investing Cash Flow	$151.9M	$188.8M+236.5%	$56.1M+39.2%	$40.3M+108.8%	-$455.4M-11385150.0%	-$4K+84.6%	-$26K-1200.0%	-$2K+83.3%	-$12K
Financing Cash Flow	-$11.0M	-$25.7M-9742.3%	$267K+3.9%	$257K-30.5%	$370K-74.7%	$1.5M-99.7%	$531.7M	N/A	$27.5M
Share Buybacks	N/A	$25.5M	$0	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$37.1M-12.8%	-$46.4M-51.8%	-$28.2M+7.2%	-$40.4M-75.3%	-$32.9M+22.1%	-$30.6M+23.3%	-$30.4M-39.2%	-$23.0M-30.9%
Depreciation & Amortization	$104K0.0%	$104K0.0%	$104K0.0%	$104K0.0%	$104K0.0%	$104K0.0%	$104K0.0%	$104K0.0%
Stock-Based Compensation	$3.4M-27.6%	$3.7M-46.4%	N/A	$4.5M-62.9%	$4.7M-63.3%	$7.0M-44.8%	N/A	$12.2M-1.8%
Investing Cash Flow	$34.3M+124.4%	$29.7M-65.3%	$46.6M+1482.6%	$41.3M+133.9%	$15.3M-87.7%	$85.6M+50.7%	-$3.4M-112.1%	-$122.0M-108.5%
Financing Cash Flow	$0+100.0%	$257K+174.1%	$0	-$11.3M-9762.4%	-$14.1M	-$347K-331.3%	$0	$117K+27.2%
Share Buybacks	N/A	N/A	$0	$11.4M	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

AVIR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AVIR quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY22DEF 14A	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Margin	N/A	N/A	N/A	N/A	39.4%+62.1pp	-22.7%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	34.4%+57.0pp	-22.5%	N/A	N/A
Return on Equity	-57.4%-19.1pp	-38.3%-13.8pp	-24.5%-6.4pp	-18.1%-35.2pp	17.0%+19.0pp	-2.0%	N/A	N/A
Return on Assets	-50.1%-14.0pp	-36.1%-13.3pp	-22.9%-5.5pp	-17.4%-33.1pp	15.7%+16.9pp	-1.3%+62.3pp	-63.6%	N/A
Current Ratio	7.82-17.0x	24.85+6.6x	18.24-17.5x	35.77+22.2x	13.58+10.8x	2.73-6.3x	9.00	N/A
Debt-to-Equity	0.14+0.1x	0.060.0x	0.070.0x	0.040.0x	0.09-0.5x	0.58	N/A	N/A
Asset Turnover	N/A	N/A	N/A	N/A	0.45+0.4x	0.06	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	-24.8%	610.1%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-16.1%-5.9pp	-19.4%-11.1pp	N/A	-13.3%-6.5pp	-10.2%-1.7pp	-8.3%+4.2pp	N/A	-6.8%-1.1pp
Return on Assets	-14.2%-4.7pp	-17.0%-9.2pp	N/A	-12.3%-5.9pp	-9.5%-1.6pp	-7.8%+3.6pp	N/A	-6.3%-0.9pp
Current Ratio	8.13-11.0x	7.89-12.1x	7.82-17.0x	16.66-2.7x	19.17+0.1x	19.94+6.7x	24.85+6.6x	19.33-12.6x
Debt-to-Equity	0.14+0.1x	0.14+0.1x	0.14+0.1x	0.090.0x	0.070.0x	0.070.0x	0.060.0x	0.070.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Atea Pharmaceuticals, Inc. AVIR	FY2025	N/A	-$158.0M	N/A	$406.6M	—
Neumora Therapeutics, Inc. NMRA	FY2025	N/A	$236.9M	N/A	$98.7M	—
Omeros Corporation OMER	FY2025	N/A	N/A	N/A	$1.4B	—
Candel Therapeutics, Inc. CADL	FY2025	N/A	-$38.2M	N/A	$782.8M	—
RAPT Therapeutics, Inc. RAPT	FY2024	N/A	-$129.9M	N/A	$1.7B	—
Invivyd, Inc. IVVD	FY2025	$53.4M	-$52.5M	-98.3%	$247.4M	68/100

Where Atea Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. profitable?

No, Atea Pharmaceuticals, Inc. (AVIR) reported a net income of -$158.0M in fiscal year 2025.

What is Atea Pharmaceuticals, Inc.'s EBITDA?

Atea Pharmaceuticals, Inc. (AVIR) had EBITDA of -$180.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Atea Pharmaceuticals, Inc.'s return on equity (ROE)?

Atea Pharmaceuticals, Inc. (AVIR) has a return on equity of -57.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Atea Pharmaceuticals, Inc.'s operating cash flow?

Atea Pharmaceuticals, Inc. (AVIR) recorded an outflow of $132.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Atea Pharmaceuticals, Inc.'s total assets?

Atea Pharmaceuticals, Inc. (AVIR) had $315.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Atea Pharmaceuticals, Inc. spend on research and development?

Atea Pharmaceuticals, Inc. (AVIR) invested $148.0M in research and development during fiscal year 2025.

Does Atea Pharmaceuticals, Inc. buy back shares?

Yes, Atea Pharmaceuticals, Inc. (AVIR) spent $25.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Atea Pharmaceuticals, Inc. have outstanding?

Atea Pharmaceuticals, Inc. (AVIR) had 80M shares outstanding as of fiscal year 2025.

What is Atea Pharmaceuticals, Inc.'s current ratio?

Atea Pharmaceuticals, Inc. (AVIR) had a current ratio of 7.82 as of fiscal year 2025, which is generally considered healthy.

What is Atea Pharmaceuticals, Inc.'s debt-to-equity ratio?

Atea Pharmaceuticals, Inc. (AVIR) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Atea Pharmaceuticals, Inc.'s return on assets (ROA)?

Atea Pharmaceuticals, Inc. (AVIR) had a return on assets of -50.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Atea Pharmaceuticals, Inc.'s P/E ratio?

Atea Pharmaceuticals, Inc. (AVIR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $406.6M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Atea Pharmaceuticals, Inc.'s price-to-sales ratio?

Atea Pharmaceuticals, Inc. (AVIR) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $406.6M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Atea Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Atea Pharmaceuticals, Inc. (AVIR) held $301.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $132.0M over that year. Dividing the one by the other, the reported balance equals about 27 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Atea Pharmaceuticals, Inc.'s Piotroski F-Score?

Atea Pharmaceuticals, Inc. (AVIR) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Atea Pharmaceuticals, Inc.'s earnings high quality?

Atea Pharmaceuticals, Inc. (AVIR) reported a net loss of $158.0M while operations used $132.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.